Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2026
Prognostic Value of Computational Pressure-Flow Dynamics Derived FFR Measured Immediately After Successful Paclitaxel‑Coated Balloon Angioplasty for In-Stent Restenosis Lesion.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yang Wangwei, He Xingqiang, Liu Jianzheng, Mou Fangjun, Liu Yi, Yin Zhiyong, Li Fei, Zhou Jingyu, Gao Haokao, Hu Tao, van Geuns Robert-Jan, Onuma Yoshinobu, Serruys Patrick W, Gao Chao, Tao Ling
Аннотация
BACKGROUND: The clinical impact of angiography-based, computational pressure-flow dynamics derived FFR (caFFR) after paclitaxel‑coated balloon (DCB) angioplasty remains unclear.
AIMS: To investigate the prognostic value of post-procedural caFFR in the treatment of in-stent restenosis (ISR) with DCB.
METHODS: Consecutive patients undergoing DCB angioplasty for ISR at Xijing Hospital, China, between December 2015 and December 2019 were prospectively enrolled. The primary endpoint was vessel-oriented composite endpoint (VoCE), defined as a composite of vessel-related cardiovascular death, target-vessel myocardial infarction (TV-MI), and ischemia-driven target vessel revascularization (ID-TVR) at 3-year, assessed at the vessel level.
RESULTS: A total of 1055 vessels treated with DCB were screened, and the post-procedural caFFR was analyzable in 999 (94.7%). At 3-year, 149 VoCE (14.9%) and 98 ID-TVR (9.8%) events occurred. Maximally-selected log-rank statistics respectively identified post-procedural caFFR value of 0.87 and post-procedural %DS of 28 as the optimal cutoff points to predict VoCE. Post-procedural caFFR demonstrates the superior predictive ability for VoCE compared to post-procedural %DS (NRI: 7.4%, p < 0.001). A negative correlation was discerned between post-procedural caFFR value and VoCE (HRper 0.1 increase: 0.72, 95% CI: 0.53-0.98, p = 0.039). Post-procedural caFFR ≤ 0.87 group was associated with a 1.5-fold increase in the risk of VoCE (HRIPTW: 1.53, 95% CI: 1.02-2.29) and a 1.8-fold increase in ID-TVR (HRIPTW: 1.82, 95% CI: 1.15-2.89).
CONCLUSIONS: A higher post-procedural caFFR value is associated with improved vessel-related clinical outcomes in patients of ISR treated by DCB. Achieving a post-procedural caFFR value of 0.87 in the treated vessels may represent a reasonable procedural goal.
TRIAL REGISTRATION: Clinicaltrial.gov identifier: NCT05133921.
AIMS: To investigate the prognostic value of post-procedural caFFR in the treatment of in-stent restenosis (ISR) with DCB.
METHODS: Consecutive patients undergoing DCB angioplasty for ISR at Xijing Hospital, China, between December 2015 and December 2019 were prospectively enrolled. The primary endpoint was vessel-oriented composite endpoint (VoCE), defined as a composite of vessel-related cardiovascular death, target-vessel myocardial infarction (TV-MI), and ischemia-driven target vessel revascularization (ID-TVR) at 3-year, assessed at the vessel level.
RESULTS: A total of 1055 vessels treated with DCB were screened, and the post-procedural caFFR was analyzable in 999 (94.7%). At 3-year, 149 VoCE (14.9%) and 98 ID-TVR (9.8%) events occurred. Maximally-selected log-rank statistics respectively identified post-procedural caFFR value of 0.87 and post-procedural %DS of 28 as the optimal cutoff points to predict VoCE. Post-procedural caFFR demonstrates the superior predictive ability for VoCE compared to post-procedural %DS (NRI: 7.4%, p < 0.001). A negative correlation was discerned between post-procedural caFFR value and VoCE (HRper 0.1 increase: 0.72, 95% CI: 0.53-0.98, p = 0.039). Post-procedural caFFR ≤ 0.87 group was associated with a 1.5-fold increase in the risk of VoCE (HRIPTW: 1.53, 95% CI: 1.02-2.29) and a 1.8-fold increase in ID-TVR (HRIPTW: 1.82, 95% CI: 1.15-2.89).
CONCLUSIONS: A higher post-procedural caFFR value is associated with improved vessel-related clinical outcomes in patients of ISR treated by DCB. Achieving a post-procedural caFFR value of 0.87 in the treated vessels may represent a reasonable procedural goal.
TRIAL REGISTRATION: Clinicaltrial.gov identifier: NCT05133921.
Предметные рубрики MeSH
HumansPaclitaxelAngioplasty, Balloon, CoronaryPredictive Value of TestsCoronary RestenosisTime FactorsFractional Flow Reserve, MyocardialTreatment OutcomeCardiovascular AgentsProspective StudiesCoated Materials, BiocompatibleFemaleMaleCardiac CathetersAgedMiddle AgedRisk FactorsCoronary Artery DiseaseCoronary AngiographyStentsChinaPercutaneous Coronary InterventionDrug-Eluting Stents